ABSTRACT
While enormous efforts are directed at tackling the problems of human tuberculosis (TB) globally, the aspect of bovine TB (bTB) has received limited attention particularly in developing countries, where control policies are non-existent or inadequate. We compared the results of a single intradermal comparative cervical tuberculin test (SICCTT) with cytokine profiles before and after anti-helminthic treatment in cattle in their natural environment. Cattle were initially subjected to SICCTT and their helminth status assessed by coprological testing for Strongyle-type, Strongyloides sp., Toxocara vitulorum, Nematodirus sp., Paraphistomum cervi, Fasciola gigantica, Dicrocoelium dendriticum and Moniezia benedeni.; 60 days after, they were dewormed and the SICCTT was repeated with coprological testing; SICCTT-positives underwent post mortem examination and mycobacterial culture to confirm TB infection. Also, we measured the level of circulating type 1 (gamma interferon [IFN-γ]), type 2 (interleukine-4 [IL-4]) and regulatory (transforming growth factor-beta [TGF-β]) cytokines before and after anthelminthic therapy. Results revealed that cattle positive by SICCTT showed typical granulomatous lesions suggestive of TB which was confirmed by positive culture. The proportion of SICCTT positive cattle increased to about two folds following anthelminthic treatment. Cattle co-infected with helminth-bTB have significantly (p = 0.000) lower levels of IFN-γ and higher levels of IL-4 and TGF-β. Conversely, anthelminthic therapy led to significantly (p=0.000) elevated levels of IFN-γ, concomitant (p =0.000) decreased levels of IL-4 and TGF-β. Overall, we show that anthelminthic treatment can improve the rate of SICCTT positivity and reverse the modulation of cytokine responses in helminth-bTB co-infection.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical permit for this study was given by the University of Ibadan-Animal Care and Use Research Ethics Committee (No. UI-ACUREC/19/138). Furthermore, all methods were performed following the relevant guidelines and regulations
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All the data used for this study will be made available on request by simeonc5{at}gmail.com AND akinseye.toyin{at}gmail.com
